ArticleActa pharmaceutica Sinica. B2026

Targeting the SETD2-FTO-KIT pathway as a pharmacological strategy for TKI-refractory GIST.

Zhi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.